Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

North Texas health officials said they are keeping a close eye on the spread in outbreak communities and have plans in place ...

Werewolf Therapeutics provided a business update, announcing progress in their clinical trials for WTX-124, a conditionally activated therapeutic for cutaneous melanoma, with full enrollment in ...

Reports Q4 revenue $0 vs. $301,590. “Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor ...

Bruker Corporation (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology at the 2025 ...

The Midland Chamber of Commerce hosted their 4th Annual WTX Women’s Symposium. The event is designed to empower women in ...